IRCT201109067482N1
Completed
未知
Differential effects of metformin and pioglithazone on hs-CRP in patients with type II DM.
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- diabetes mellitus II.
- Sponsor
- Qazvin University of Medical Sciences
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diabetic patients (type 2\) receiving diet or monotherapy by sulphonylurea, HbA1C\=7\.5 and FBS\=140
- •Exclusion criteria: known case of inflammatory disease such as IBD, RA, vascultis, recent infection in one month suffering from malignancy, receiving other drug that decrease CRP level .\[COX inhibitor (ASA, Celecoxib ), platlete aggregation inhibitor (clopidogrel, abciximab ), lipid lowering agents (Statins, Ezetimibe, Fenofibrate, Niacin, B blockers, antioxidants (vit E), ACEIs, ARBs ,CCBs except Amlodipine, Tamoxifen], Soye isoflavon enriched food; consumption of oral estrogen that increase CRP level, hypersensitivity to Metformin or Pioglitazone, Insulin use, Corticosteroid use, Cr \>1\.4 mg/dl, severe abnormal liver function test, pregnancy
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Effect of Metformin & Glutazon on cardiovascular diseaseDiabetes.Diabetes mellitusE10-14IRCT2013041311356N2Tehran University of Medical Sciences100
Completed
Not Applicable
Effect of pioglitazone and metformin in combination with insulin therapy in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000003830Chigasaki Municipal Hospital250
Completed
Not Applicable
Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetestype 2 diabetesJPRN-UMIN000001891Jikei University School of Medicine20
Completed
Phase 4
To study the differences in the effects of various drugs in patients suffering from metabolic syndrome, which is a cluster of conditions such as obesity, increased blood pressure and disordered cholesterol levels that increases the risk of heart diseases, diabetes and stroke.Health Condition 1: null- Metabolic SyndromeCTRI/2014/10/005139Department of Pharmacology140
Completed
Not Applicable
Evaluation of possible cause of weight change after Metformin and pioglitazone administration in patients with type 2 diabetesIRCT201102275917N1Vice chancellor for Research, Tehran university of medical science (TUMS)60